GLPG 1972

Drug Profile

GLPG 1972

Alternative Names: GLPG1972; S 201086

Latest Information Update: 11 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galapagos NV
  • Developer Galapagos NV; Servier
  • Class Antirheumatics; Small molecules
  • Mechanism of Action ADAMTS5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Osteoarthritis

Most Recent Events

  • 07 Jan 2018 Galapagos and Servier plans a global phase II trial for Osteoarthritis in 2018
  • 07 Jan 2018 Adverse events data from a phase Ib trial in Osteoarthritis released by Galapagos
  • 03 Nov 2017 Pharmacokinetics data from a phase I trial in Healthy volunteers presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top